Mavatar expands access to DINA drug development analysis software
Data analytics firm Mavatar is opening its biological intelligence platform to additional pharmaceutical companies to help identify viable drug development candidates.
Mavatar has announced a broader rollout of its DINA technology, a platform designed to assist pharmaceutical and biotech firms in evaluating the viability of drug development programs. The software uses biomedical data to create digital disease models, aiming to increase the success rates of clinical trials.
Industry data shows that approximately one in 29 cancer drugs entering human trials receives final regulatory approval. By identifying which research programs lack biological potential early in the development cycle, Mavatar intends to help developers allocate resources to projects with a higher probability of success.
The DINA platform provides traceable data sources for its findings, allowing researchers to verify the information behind each model. The company, which already maintains partnerships with firms including Sobi, is now positioning the technology for wider industry adoption to streamline research and development workflows.